In conclusion our data indicates that CD25 enrichment post CMV stimulation in G-CSF-mobilized PBMCs results in the simultaneous generation of a functional mixed population of CMV-T and Tregs and outlines a potential therapeutic strategy for the treatment of both GvHD and CMV reactivation following HSCT. The gene discussed is CSF3; the disease is graft versus host disease.